Abstract: A key fob-control unit pairing device that includes a transceiver to transmit and receive signals, a memory to store a key fob identification (KFID) and a control unit identification (CUID), and a processor coupled to said transceiver and memory. The processor is to authenticate the key fob using identification (ID) authenticated key agreement protocol based on the KFID, and to transmit an encrypted CUID to the key fob.

Abstract: An imaging agent for detecting analytes in a biological environment includes functionalized, silicon vacancy center-containing nanodiamonds. Individual nanodiamonds of the imaging agent include at least one silicon vacancy center. The at least one silicon vacancy center can emit light having a wavelength in a narrow band in response to illumination having any wavelength in a wide range of wavelengths. The nanodiamonds are functionalized to selectively interact with an analyte of interest. The nanodiamonds can additionally include other color centers, and the imaging agent can include a plurality of sets of nanodiamonds having detectably unique ratios of silicon vacancy centers to other color centers. The silicon vacancy centers in the nanodiamonds can have a preferred orientation enabling orientation tracking of individual nanodiamonds or other applications. A method for detecting properties of the analyte of interest by interacting with the imaging agent is also provided.

Abstract: Systems and methods for vertical takeoff and/or landing are disclosed herein. An aerial vehicle may include a first propulsion unit and a second propulsion each rotatably connected to a body. The aerial vehicle may include a first wing and a second wing each rotatably connected to the body. And the aerial vehicle may include a control system configured to: position the first propulsion unit, the second propulsion unit, the first wing, and the second wing; operate the first propulsion unit and the second propulsion unit; and rotate the first propulsion unit, the second propulsion unit, the first wing, and the second wing.

Abstract: A method and system for measurement of ground based vehicle speed includes a movable platform that includes an unmanned aerial vehicle (UAV) located in proximity to a roadway, the UAV operates under control and navigation of a UAV control unit, and the UAV also carries camera and monitoring equipment, the camera and monitoring equipment including an onboard computing system, and a camera with a wide angle lens and a camera with a telephoto lens, the cameras being mounted on a pan/tilt device. An algorithm operated by the on-board computing system is used to detect and track vehicles moving on a roadway. The algorithm is configured to detect and track the vehicles despite motion created by movement of the UAV. The cameras mounted on the pan/tilt device are moved under the direction of the computer vision algorithm to maintain a target vehicle of the detected moving vehicles in view, and the speed of the target vehicle is measured.

Abstract: Embodiments described herein may help to provide medical support via a fleet of unmanned aerial vehicles (UAVs). An illustrative medical-support system may include multiple UAVs, which are configured to provide medical support for a number of different medical situations. Further, the medical-support system may be configured to: (a) identify a remote medical situation, (b) determine a target location corresponding to the medical situation, (c) select a UAV from the fleet of UAVs, where the selection of the UAV is based on a determination that the selected UAV is configured for the identified medical situation, and (d) cause the selected UAV to travel to the target location to provide medical support.

Abstract: Devices and methods for transmucosal drug delivery are provided. A device includes a housing configured for intralumenal deployment into a human or animal subject; a drug-dispensing portion which contains at least one drug; and a plurality of microneedles extending, or being extendable from, the housing, the plurality of microneedles being configured to disrupt at least one region of a mucosal barrier adjacent the housing at a selected time after being intralumenally deployed in the human or animal subject. The device is operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the plurality of microneedles.

Abstract: A method for modulating a response signal includes introducing functionalized particles into a lumen of subsurface vasculature, wherein the functionalized particles are configured to interact with one or more target analytes present in blood circulating in the subsurface vasculature; and non-invasively detecting the one or more target analytes. A response signal, which may include a background signal and an analyte response signal related to interaction of the functionalized particles with the one or more target analytes, is transmitted from the subsurface vasculature. A modulation configured to alter the response signal such that the analyte response signal is affected differently than the background signal may be applied to a portion of subsurface vasculature. Analyte detection may be achieved by differentiating the analyte response signal from the background signal.

Abstract: A method for modulating a response signal includes introducing functionalized magnetic particles configured to interact with target analytes into the body, applying a magnetic field sufficient to draw the functionalized magnetic particles towards a surface of the lumen of subsurface vasculature closest to an internally or externally applied mask having a spatial arrangement, and detecting a response signal, which includes a background signal and an analyte response signal, transmitted from the subsurface vasculature. The analyte response signal related to interaction of the functionalized magnetic particles with the target analytes and is modulated with respect to the background signal due, at least in part, to the spatial arrangement of the mask. The target analytes may be non-invasively detected by differentiating the analyte response signal from the background signal due, at least in part, to the modulation of the analyte response signal.

Abstract: A system for modulating a response signal includes functionalized particles configured to interact with target analytes, a detector configured to detect an analyte response signal transmitted from the body, a modulation source configured to modulate the analyte response signal, and a processor configured to non-invasively detect the one or more target analytes by differentiating the analyte response signal from a background signal, at least in part, based on the modulation. The analyte response signal is related to the interaction of the target analytes with the functionalized particles. In some examples, the system may also include magnetic particles and a magnetic field source sufficient to distribute the magnetic particles into a spatial arrangement in the body. The analyte response signal may be differentiated from the background signal, at least in part, based on modulation of the signals due, at least in part, to the spatial arrangement of the magnetic particles.

Abstract: Intralumenal devices and methods are provided for transmucosal drug delivery. The device may comprise a housing configured for intralumenal deployment into a human or animal subject; a drug-dispensing portion which contains at least one drug; and an electrically-actuatable portion configured to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the electrically-actuatable portion.

Abstract: A method and apparatus for enabling themes using photo-active surface paint is described. The method may include capturing image data with at least a camera of a painted surface display system. The method may also include analyzing the image data to determine a real-world context proximate to a painted surface, wherein the surface is painted with a photo-active paint. The method may also include selecting a theme based on the determined real-world context. The method may also include generating a theme image, and driving a spatial electromagnetic modulator to emit electromagnetic stimulation in the form of the theme image to cause the photo active paint to display the theme image.

Abstract: A reimageable layer of an imaging member is provided with a dampening fluid layer. The reimageable layer has specific properties such as composition, surface profile, and so on so as to be well suited for receipt and carrying the dampening fluid layer. An optical patterning subsystem such as a scanned modulated laser patterns the dampening fluid layer. Ink having a first set of properties such as color, composition, etc., is applied at an inking subsystem such that it selectively resides in voids formed by the patterning subsystem in the dampening fluid layer to thereby form an inked latent image. The inked latent image is then transferred to a substrate, and the reimageable surface cleaned. The process is repeated for a second ink having properties different than the first. Each ink image may successively be applied to the substrate, or a composite image may be formed then applied to the substrate.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Abstract: Devices and methods are provided for drug delivery. The device may include a housing configured for intralumenal deployment into a human or animal subject and first and second reservoirs within the housing, each reservoir having an actuation end, an opposed release end, and a plug moveable from the actuation end toward the release end. First and second drug formulations may be contained in the first and second reservoirs, respectively. The device may also include one or more actuation systems configured to drive the first and second plugs so as to drive the first and second drug formulations from the first and second reservoirs. The housing may include a porous membrane sidewall in fluid communication with the release ends of the first and second reservoirs, the porous membrane sidewall being configured to distribute the first and second drug formulations driven from the first and second reservoirs.

Abstract: Embodiments described herein may relate to an unmanned aerial vehicle (UAV) navigating to a target in order to provide medical support. An illustrative method involves a UAV (a) determining an approximate target location associated with a target, (b) using a first navigation process to navigate the UAV to the approximate target location, where the first navigation process generates flight-control signals based on the approximate target location, (c) making a determination that the UAV is located at the approximate target location, and (d) in response to the determination that the UAV is located at the approximate target location, using a second navigation process to navigate the UAV to the target, wherein the second navigation process generates flight-control signals based on real-time localization of the target.

Abstract: An illustrative emergency-support system may include multiple unmanned aerial vehicles (UAVs), which are configured to provide emergency support for a number of different emergency situations. Further, the emergency-support system may be configured to: (a) identify a request for assistance in a remote emergency situation, (b) identify a remote device associated with the request for assistance, (c) determine a target location corresponding to the emergency situation, (d) control a UAV to travel to the target location to provide emergency support, and (e) enable an otherwise restricted capability of one or more of the remote device or the UAV after controlling the UAV to travel to the target location, wherein the capability is enabled to help provide emergency support in the remote emergency situation.

Abstract: Devices and methods are provided for transmucosal drug delivery. The transmucosal drug delivery device may include a housing configured for intralumenal deployment, such as intravaginally, into a human or animal subject; a drug-dispensing portion which contains at least one drug, the drug-dispensing portion being configured to dispense the drug from the housing by positive displacement; and a permeability enhancer-dispensing portion configured to release or generate a permeability enhancing substance to disrupt at least one region of a mucosal barrier adjacent to the housing at a selected time while intralumenally deployed in the human or animal subject. The device may be operable to dispense the drug from the housing to a region of the mucosal barrier disrupted by the permeability enhancing substance.

Abstract: A dampening fluid useful in offset ink printing applications contains water and a surfactant whose structure can be altered. The alteration in structure aids in reducing accumulation of the surfactant on the surface of an imaging member. The surfactant can be decomposed, switched between cis-trans states, or polymerizable with ink that is subsequently placed on the surface.

Abstract: Embodiments described herein may relate to an unmanned aerial vehicle (UAV) navigating to a medical situation in order to provide medical support. An illustrative method involves a UAV (a) housing a medical-support device, (b) determining a target location associated with at least one individual in need of medical assistance, (c) navigating the UAV from a remote location to the target location, (d) the computing system making a determination that the UAV is located at the target location, and (e) in response to the determination that the UAV is located at the target location, delivering by a delivery mechanism the medical-support device for providing medical assistance for the at least one individual in need of medical assistance.